Gyros previews next generation of Gyrolab Workstation for protein quantification at nanoliter scale


Gyros has decided to preview Gyrolab Workstation, with its new laser-induced fluorescence detector for protein quantification, at the American Society of Mass Spectrometry meeting in Montreal, Canada, June 8-12. Those who attend will have a possibility to obtain more information.

The concept was presented at a recent meeting of the American Association of Immunologists. “Scientists can now run established sandwich-based immunoassays at nanoliter scale in a CD microlaboratory.” explained Per Sjöberg, Executive Vice-President Marketing and Sales at Gyros AB, “Gyrolab Bioaffy and our sample preparation CD, Gyrolab MALDI, are both run on Gyrolab Workstation, demonstrating the flexibility of Gyros technology platform. Users can benefit from a single instrument that runs different application CDs as required.”

Mr. Sjöberg continued, “Our development strategy is to focus on areas in which miniaturization and integration of protein applications into a CD microlaboratory have clear advantages. Gyrolab Bioaffy will allow the customer to assay their proteins in a format optimized for working with small volumes and many samples. Working at nanoliter scale will give a major reduction in sample and reagent consumption per data point. Many time-consuming and costly investigations caused by limited availability of sample, such as biomarker profiling in small animal models, can be reduced to days rather than weeks since more proteins can be assayed in a single sample.”

Mr. Sjöberg added. “Demonstrations and customer collaborations can be performed at our facilities in Princeton, New Jersey and in Uppsala, Sweden. Anyone with a serious interest is welcome to contact their Gyros representative to arrange a visit.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.